Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    FDA Requests Boxed Warnings on Conventional Antipsychotic Drugs - (DGNews)
    Pramlintide-Related Improvements in Diabetes Benefit Patients' Psyche: Presented at ADA - (DGDispatch)
    Health Canada Approves New Treatment for Bipolar Mania - (DGNews)
    Report Confirms Increased Risk of Smoking, Substance Abuse in Bipolar Adolescents - (DGNews)
    Short-Term Antipsychotics in Older Adults With Dementia Associated With Serious Adverse Events - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Prevalence and Associated Factors for Suicidal Ideation and Behaviors in Obsessive-Compulsive Disorder
      Delirium Update
      The Pharmacist's Role in Breaking the Cycle of PMDD
      Understanding Autism: The Role of the Pharmacist in the Management of Autism

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Childhood Autism in a 13 Year Old Boy with Oculocutaneous Albinism: A Case Report
        Unexpected Depletion in Plasma Choline and Phosphatidylcholine Concentrations in a Pregnant Woman with Bipolar Affective Disorder Being Treated with Lithuim, Haloperidol and Benztropine: A Case Report
        Recognizing Thyrotoxicosis in a Patient with Bipolar Mania: A Case Report

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        New Cautions Regarding Rare Heart-Related Risks for All ADHD Drugs

        OTTAWA, CANADA -- May 26, 2006 -- Health Canada has revised the prescribing and patient information for all drugs used for the management of ADHD (attention deficit hyperactivity disorder) and advises Canadians not to use them if they have high blood pressure, heart disease or abnormalities, hardening of the arteries or an overactive thyroid gland.

        The new prescribing and patient information applies to both adults and children.

        Standardized labeling that identifies risk factors for rare heart-related side effects, and new recommendations to physicians have been added to the prescribing information for the following drugs, and for any products containing these drugs:

        Adderall XRŽ mixed salts amphetamine extended-release
        Attenade™ dextromethylphenidate [approved by Health Canada, but the manufacturer has not marketed in Canada]
        BiphentinŽ methylphenidate controlled release [approved by Health Canada, but the manufacturer has not marketed in Canada]
        Concerta* methylphenidate extended release
        DexedrineŽ dextroamphetamine
        RitalinŽ methylphenidate
        Ritalin SRŽ (methylphenidate extended release)
        StratteraŽ atomoxetine

        * Trademark used under licence to Janssen-Ortho Inc.

        ADHD drugs are generally safe and provide benefits for Canadians and their treatment of ADHD when used as directed. Decisions about taking any of the drugs are best made in consultation with a physician.

        Before using these drugs, patients should inform their doctor if they are involved in strenuous exercise or activities, are using other drugs for ADHD, have certain heart-related conditions or have a family history of sudden cardiac death. Health Canada stresses that patients should not stop taking ADHD medication without first consulting their doctors.

        All ADHD drugs stimulate the heart and blood vessels (cardiovascular system). The effects are usually mild or moderate, but in some patients, this stimulation may – in rare cases – result in cardiac arrests, strokes or sudden death.

        Patients taking ADHD drugs should consult with their physician if they have any questions or concerns.

        Health Canada continues to monitor the safety of these drugs and Canadians will continue to be informed if new concerns arise. For more information, please see the Health Canada letter to healthcare professionals regarding this issue.

        To report a suspected adverse reaction to ADHD drugs, please contact the Canadian Adverse Drug Reaction Monitoring Program (CADRMP) of Health Canada by one of the following methods:
        Telephone: 866-234-2345 Facsimile: 866-678-6789

        CADRMP
        Marketed Health Products Directorate
        Health Protection Building, Tunney's Pasture, AL 0701C
        Ottawa, ON
        K1A 0K9
        Email: cadrmp@hc-sc.gc.ca


        SOURCE: Health Canada



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send